Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
Huawu Xiao, Xiuchun Chen, Huimin Lv, Fangzhou Xia et al.
Citations
8 citations
Journal
EClinicalMedicine
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
1.98
article
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
Qingdao University (CN), Central South University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Zhengzhou University (CN), Hunan Cancer Hospital (CN), Affiliated Hospital of Qingdao University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Henan Cancer Hospital (CN), Jiangsu Hengrui Medicine (China) (CN), Xinxiang Central Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Qilu Hospital of Shandong University (CN), University of Chinese Academy of Sciences (CN), China Medical University (CN)